Hence, translating our findings to clinical practice could be accelerated by a filtered retrospective analysis of the WES/WGS data previously obtained by others, focused on the TMCC2 genetic variants in patients with various bone marrow failure conditions, especially in a cohort of CDA patients. This evidence concerns the gene TMCC2 and congenital dyserythropoietic anemia.